CREBBP and acute myeloid leukemia: Overall, p300/CBP inhibitors in combination with FLT3 inhibitors synergistically suppress p300/CBP targets and FLT3 signaling, resulting in augmented antitumor effects against FLT3-ITD AML both in vitro and in vivo.